Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Sponsor
Novo Nordisk A/S
Study ID
NCT01513525
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits

Study Details

This trial is conducted in Europe. the aim of this trial is to compare the pharmacokinetic profile of liraglutide between administrations in the thigh versus the abdomen and between administrations in the upper arm versus the abdomen.

Key Dates

Start date
Feb 28, 2007
Status verified
Jan 2017
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
21 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Abdomen
  • Experimental: Thigh
  • Experimental: Upper arm

Primary Outcome Measure

Area under the Curve (AUC) of liraglutide for each injection site

Related Studies